Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 51

DEA Clinical Trials THC Research and Development 51

SpeedWeed

MAY 24, 2021

The Drug Enforcement Administration made a milestone announcement earlier this month with the news that the DEA will begin granting marijuana cultivation licenses to various third-party applicants, significantly expanding medical and scientific cannabis research in the United States.

DEA 52

DEA Cultivation Research and Development Marijuana 52

The Blunt Truth

MAY 15, 2020

We’ve got an update on the latest Montana legalization developments. The news on access to loans and other support from the Small Business Administration was less rosy. marijuana research. The big news this week is that cannabis banking is included in the latest federal relief bill. SBA funds, however, are not.

Banking 106

Banking Research and Development Programs Advocacy 106

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. Patients Are Not In This Alone.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Canna Law Blog

MARCH 4, 2020

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).

Therapy 121

Therapy Legalization Chronic Pain DEA 121

SpeedWeed

AUGUST 7, 2021

Democratic leaders in both chambers of Congress have come up with a new plan that would make it easier for scientists to access high-quality cannabis for research. . But the bill also includes additional provisions to ensure that scientists will be able to use high-quality cannabis to conduct this research.

DEA 52

DEA Research and Development Legalization Strains 52

Cannabis Law Report

DECEMBER 15, 2021

Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin-containing mushrooms for authorized research purposes. “Having a supply partner that gives us access to the rapidly growing U.S. “With their track-record of working with the U.S.

Supply Chain 52

Supply Chain Research and Development DEA Pharmaceutical 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.

Research and Development 102

Research and Development Therapy Consumption DEA 102

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?

Law 81

Law Research and Development Therapy DEA 81

The Cannigma

MAY 16, 2025

So while a cannabis business can join their local chamber of commerce, a patient in hospice can be denied access to medical cannabis. The unstable legality of federal protections for medical cannabis, which solely come from an amendment to the DOJ and DEAs budget that has to pass every year, threatens our progress. Make it make sense.

Policy 105

Policy Access Advocacy Patients 105

Veriheal

MARCH 6, 2024

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The other big change that comes with rescheduling is an increase in cannabis research opportunities. billion in excess taxes when compared to non-cannabis businesses.

Research and Development 64

Research and Development DEA Chronic Pain Business 64

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits.

Legalization 111

Legalization Decriminalization Medicine Research and Development 111

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. The Next Move Is On The DEA. FDA Grants Approval of Epidiolex.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level. 360bbb-0a.

Law 81

Law Therapy Clinical Trials Research and Development 81

Cannabis Law Report

JANUARY 23, 2020

This paper shall give a condensed overview over the status quo in Thailand and the potential emerging from the ongoing developments.” This paper shall give a condensed overview over the status quo in Thailand and the potential emerging from the ongoing developments. $16. It can be downloaded at: [link]. cannabis programm. $4b.

Research and Development 59

Research and Development Oil Cultivation DEA 59

Veriheal

JUNE 24, 2021

health official reportedly slammed “ongoing federal restrictions that are inhibiting research into marijuana”. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . The full statement.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Veriheal

DECEMBER 1, 2020

When it comes to scientific research and the way of Delta-8-THC, it is scarce. The DEA is Already Interfering. In August of this year, little to most people’s knowledge, the DEA continued their draconian stance against cannabis by proposing that THC derivatives also be classified as schedule one controlled substances.

THC 52

THC DEA Research and Development Cannabinoids 52

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Sensi Seeds

NOVEMBER 28, 2018

But in an email correspondence conducted as research for this article, EFSA denies issuing any statement in relation to CBD in Spain. Food and Drug Administration (FDA) earlier this year, and convince the DEA to reclassify CBD from a Schedule I (most restrictive category) to a Schedule V drug (least restrictive category.)

CBD 71

CBD Seed-To-Sale Food Research and Development 71

Cannabis Law Report

AUGUST 12, 2022

Obtaining DEA License to Grow Psilocybin Mushrooms. This panel would explore topics such as the ethical implications of psychedelic-based drug development and patenting, as well as the debate over producing and marketing natural versus synthetic psychedelics. Here are some psychedelics panel options: .

Research and Development 52

Research and Development Topical Events Policy 52

Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization 60

Decriminalization Policy Research and Development Data 60

Cannabis Law Report

SEPTEMBER 1, 2021

3] Further, notwithstanding the determination of the Drug Enforcement Administration (DEA), which is required to defer to the Department of Health and Human Services’ assessment that cannabis has no acceptable medical utility, 37 states and four territories have enacted laws allowing for the medical use of cannabis products. [4] Gordon Gray.

Policy 100

Policy Cannabis Law Treatment 100

SMPL

AUGUST 14, 2019

That includes a lack of access to financial services that lead such companies to operate on a largely cash basis, making them targets for crime. The final part of the resolution discusses the need to support research into cannabis. One area that could be quickly improved is in the sourcing of research-grade marijuana.

Policy 40

Policy Research and Development Marijuana DEA 40

Cannabis Info

OCTOBER 4, 2019

Cannabis and cannabinoids are not a tiny project — one compound for one disease — however, I show that it is really a very, very wide field of research,” Mechoulam stated. “We Demetrix is licensed by the DEA to do analysis with pure cannabinoid compounds. “Collaboration is absolutely a necessity.

Cannabinoids 45

Cannabinoids THC Wellness and Beauty Research and Development 45

Kind Meds (Cannabis Education Blog)

SEPTEMBER 4, 2019

While the FDA continues to choke the progression of research and scientific developments regarding marijuana, it simultaneously cracks down on the big players of our industry. This ease of accessibility culture has paved the fierce competition in the edibles market, for example. Here’s why. Think of Uber and Lyft.

Dispensary 69

Dispensary Research and Development Pets Patients 69

Cannabis Law Report

JULY 14, 2021

“Closing the door on broadly supported incremental reforms like the SAFE Banking Act while the Senate seeks compromise on farther-reaching bills hurts the possibilities for consensus and ignores the very real needs of small business operators who have repeatedly said that access to banking services and traditional lending is an existential issue.

Legislation 71

Legislation Banking History Access 71

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. This process should also ensure appropriate funding allocated for this research.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

The Joint Blog

JUNE 4, 2021

Believe it or not, you actually need a license to do meaningful research on marijuana due to the fact that the United States Drug Enforcement Agency (DEA) has limited its access. The DEA feels that marijuana, being a schedule I drug, could be misused like other drugs within that category and could be dangerous.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

Cannabis Law Report

JULY 30, 2019

Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Most reliable medical cannabis research filters into the U.S. through international sources, namely Israel. . Federal Register. .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

AUGUST 6, 2021

Operating expenses : Total SG&A (“SG&A”) expenses in Q1 2022 declined by 17% versus Q1 2021, driven by year-over-year reductions in General & Administrative (“G&A”) and Research and Development (“R&D”) expenses partially offset by an increase in Sales & Marketing (“S&M”) expenses. Webcast Information.

Vaping 105

Vaping Research and Development Data Business 105

Kind Meds (Cannabis Education Blog)

SEPTEMBER 4, 2019

While the FDA continues to choke the progression of research and scientific developments regarding marijuana, it simultaneously cracks down on the big players of our industry. This ease of accessibility culture has paved the fierce competition in the edibles market, for example. Here’s why. Think of Uber and Lyft.

Marijuana 40

Marijuana Research and Development Dispensary Pets 40

Cannabis Law Report

APRIL 14, 2022

Although research is still underway, the effects of both short- and long-term exposure to pesticides by consuming (i.e., pursuant to Drug Enforcement Agency (DEA) or state-level programs). by eating or smoking cannabis) are unknown. Water resource depletion has been a concern at both outdoor and indoor grow operations.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

JUNE 1, 2021

Operating expenses : Total SG&A (“SG&A”) expenses in Q4 2021 declined by 25% versus Q4 2020, driven by year-over-year reductions in Sales & Marketing, and Research and Development (“R&D”) expenses. A replay will be accessible by webcast until 11:59 PM ET on August 30, 2021 at: [link].

Data 95

Data Vaping Supply Chain Business 95

SpeedWeed

DECEMBER 28, 2018

There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. But there’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval and Big Pharma’s insatiable thirst for profits.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40